HealthDay News
Gene Tx Approved for Certain Types of B-Cell Lymphoma
October 19, 2017 (HealthDay News)
Yescarta (axicabtagene ciloleucel) has been approved by the U.S. Food and Drug Administration for individuals with certain types of...
Neurotoxicity Characterized After Infusion of CD19 CAR-T Cells
October 12, 2017 (HealthDay News)
Patients with severe neurotoxicity after infusion of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells have evidence of endothelial activation,...
ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas
December 11, 2017 (HealthDay News)
Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma
Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric...
Remission Up With T Cell Therapy for Non-Hodgkin’s Lymphoma
September 8, 2016 (HealthDay News)
Researchers identify treatment characteristics that correlate with therapeutic response, toxicity
Immunotherapy with CD19 chimeric antigen receptor (CAR)-modified T cells in a...
Case Report: Adoptive T-Cell Tx Shows Promise in Glioblastoma
December 29, 2016 (HealthDay News)
Tumors regressed after intracranial infusions of T cells engineered to target tumor-associated antigen
Treatment with autologous chimeric antigen receptor (CAR)-engineered...
New Immune Tx Achieves Remission in B-Cell Malignancies
February 16, 2016 (HealthDay News)
Patient’s T cells are engineered with chimeric antigen receptors
A new T-cell immunotherapy has led to sustained regression in many...
ASCO: CAR T-Cell Therapy Promising in Multiple Myeloma
June 6, 2017 (HealthDay News)
Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein
A new type of immunotherapy appears to...
